CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors

Part of paid clinical trials in Scottsdale, Arizona.

Sponsor
CanBas Co. Ltd.
Study ID
NCT03113188
Phase
PHASE1
Status
Completed

Conditions

  • Advanced Solid Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • CBP501 — DRUG
    CBP501, CDDP plus Nivolumab

Study Details

This is a multicenter, open-label, phase 1b study of CBP501/cisplatin/nivolumab combination administered once every 21 days to patients with advanced solid tumors.

Key Dates

Start date
Oct 25, 2017
Status verified
Oct 2020
Primary completion
Feb 15, 2021
Completion
Feb 15, 2021

Study Design

Enrollment
47 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: CBP501, CDDP, Nivolumab
    CBP501, Cisplatin and Nivolumab Administered Every 3 Weeks in Patients with Advanced Refractory Tumors

Primary Outcome Measure

Recommended dose [ Time Frame: 21 days ]

Locations (3)

FacilityCityStateZIPSite coordinators
HonorHealthScottsdaleArizona85258-
Ochsner Clinic FoundationNew OrleansLouisiana70121-
Dana Farber Cancer InstituteBostonMassachusetts02215-

Find similar trials in Scottsdale, AZ

By research site
HonorHealth· Scottsdale, AZOchsner Clinic Foundation· New Orleans, LADana Farber Cancer Institute· Boston, MA

Related Studies